Abstract 4156
Background
Based on the pivotal PALOMA trials investigating the combination of the CDK4/6 inhibitor palbociclib with letrozole or with fulvestrant after prior endocrine therapy, extended European approval was granted for this patient population to receive palbociclib in combination with any aromatase inhibitor or with fulvestrant after prior endocrine therapy. The prospective multi-centre phase 2 study INGE-B was designed to a) investigate the combination of palbociclib with letrozole or with fulvestrant in accordance with the PALOMA trials in Germany and b) to obtain so far lacking data on the combination of palbociclib with the aromatase inhibitors exemestane or anastrozole.
Methods
In total, 360 patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer were recruited at 82 sites across Germany. Eligible patients are treated with palbociclib either in combination with letrozole, anastrozole, exemestane or fulvestrant as first-line therapy or in combination with letrozole or fulvestrant as later-line therapy. Primary objective is the clinical benefit rate (CBR), defined as the percentage of patients with response or stable disease at week 24. Key secondary endpoints include progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and safety. Quality of life, fatigue, anxiety and depression are assessed with validated questionnaires. Data were analysed for each treatment group separately with descriptive statistics.
Results
The first interim analysis of the INGE-B study was scheduled to analyse data of patients receiving palbociclib and letrozole in first or later line. Between 09/2016 and 01/2018, 63 first- and 59 later-line patients were enrolled at 38 sites and observed for at least 6 months of treatment, unless discontinued earlier for disease progression or any other reason. Baseline patient and tumour characteristics will be presented. Efficacy in terms of CBR and best response and treatment-emergent adverse events will be described.
Conclusions
The results of the first interim analysis of the INGE-B study will be discussed with respect to data from the PALOMA 1/2 trials.
Clinical trial identification
NCT02894398.
Legal entity responsible for the study
iOMEDICO AG.
Funding
Pfizer.
Editorial Acknowledgement
Disclosure
D. Lüftner: Membership on an advisory board or board of directors, remunerations: Amgen, Pfizer, Eli Lilly, Celgene, Loreal. A. Welt: Membership on an advisory board or board of directors: Roche, Pfizer, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract